Abstract
Purpose
This study was designed to evaluate the antitumorigenic efficiency of Endostar (an antiangiogenic agent) arterially administrated combined with transcatheter arterial chemoembolization (TACE) on liver tumor, and validation of perfusion CT for quantitative measurements of the results.
Experimental Design
Thirty rabbits bearing VX2 liver tumors were randomly and equally distributed into three groups. One of the following treatment protocols was performed in each group: 1) group 1 was treated with TACE and simultaneously arterially administrated Endostar; 2) group 2 with TACE alone, and 3) a control group that had saline injected through hepatic artery. Routine CT scan was performed before treatment, and perfusion CT imaging was performed 2 weeks after treatment. Immunohistochemical biomarkers of microvascular density (MVD) and the expression of vascular endothelial growth factor (VEGF) were measured for assessments of angiogenesis.
Results
We observed a statistically significant reduction from the control in the volume, growth rate, and size of the tumor 2 weeks after treatment with both TACE plus Endostar and with TACE alone (P < 0.01). Although there was no statistically significant difference in tumor size between the group with TACE plus Endostar and the group with TACE alone (P > 0.05), MVD and VEGF were significantly less expressed in the TACE plus Endostar group than both groups with TACE alone and the control group (P < 0.01). Blood flow (BF), blood volume (BV), and permeability-surface area products (PS) in the group with TACE plus Endostar on perfusion CT were significantly higher than other two groups (P < 0.05), which were positively correlated with the MVD and VEGF values (P < 0.05).
Conclusions
TACE with arterial administration of Endostar simultaneously significantly inhibited the angiogenesis biomarkers associated with TACE in a rabbit model bearing VX2 liver tumor, which indicates that the combined treatment protocol may have potential synergistic effects on liver cancer. It also is suggested that perfusion CT may be useful for monitoring antiangiogenic/antivascular treatment in the liver tumors.
Similar content being viewed by others
References
Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543
Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25
Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D (2006) Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 17:217–223
Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10:1885–1889
Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878–2882
Kim YB, Park YN, Park C (2001) Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 38:160–166
Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z (2006) Effect of Transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516–521
Guo WJ, Li J, Chen Z et al (2004) Transient increased expression of VEGF and MMP-1 in a rat liver tumor model after hepatic arterial occlusion. Hepatogastroenterology 51:381–386
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other disease. Nature 407:249–257
Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333–346
Rhee TK, Young JY, Larson AC et al (2007) Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1α in rabbit VX2 liver tumors. JVIR 18:639–646
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34
O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285
Graepler F, Verbeek B, Graeter T et al (2005) Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41:879–886
Folkman J (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312:594–607
Liu F, Tan G, Li J, Dong X, Krissansen GW, Sun X (2007) Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci 98:1381–1387
Wang J, Sun Y, Liu Y et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer 8:283–290
Ling Y, Yang Y, Lu N et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79–84
Kulke MH, Bergsland EK, Ryan DP et al (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555–3561
Weidner N (1995) Intratumor mocrovessel density as a prognostic factor in cancer. Am J Pathol 147:9–19
Vermeulen PB, Gasparini G, Fox SB et al (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumors. Eur J Cancer 38:1564–1579
Fox SB (1997) Tumor angiogenesis and prognosis. Histopathology 30:294–301
Bellomi M, Viotti S, Preda L et al (2010) Perfusion CT in solid body-tumours. Part II: clinical applications and future development. Radiol Med 115(6):858–874
Avinash R et al (2009) Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 47:161–178
Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology 243:736–743
Wu HP, Feng GS, Liang HM et al (2004) Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol 10:813–818
Maataoui A, Qian J, Vossoughi D et al (2005) Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 15(1):127–133
Piguet AC, Semela D, Keogh A et al (2008) Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49(1):78–87
Kan ZX, Phongkitkarun S, Kobayashi S et al (2005) Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237:151–158
Kerbel RS (2006) Antiangiogenic therapy: a universal chemosenitizatin strategy for cancer? Science 312:1171–1175
Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987–989
Poon RT, Ng IO, Lau C et al (2001) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235
Wintermark M, Thiran JP, Maeder P, Schnyder P, Meuli R (2001) Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. Am J Neuroradiol 22:905–914
Hakimé A, Peddi H, Hines-Peralta AU et al (2007) CT perfusion for determination of pharmacologically mediated blood flow changes in an animal tumor model. Radiology 243:712–719
Kan Z, Kobayashi S, Phongkitkarun S, Charnsangavej C (2005) Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model. Radiology 237:144–150
Yoon CJ, Chung JW, Park JH et al (2003) Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229:126–131
Yoon CJ, Chung JW, Park JH et al (2004) Transcatheter arterial embolization with 188Rhenium-HDD-labeled iodized oil in rabbit VX2 liver tumor. J Vasc Interv Radiol 15:1121–1128
Acknowledgments
The authors thank Dr. Zuxing Kan, from M.D. Anderson Medical Center, for his revision and valuable comments. This project was sponsored by National Natural Science Foundation of China (NSFC#30870703, 30910103905).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00270-011-0274-z
Rights and permissions
About this article
Cite this article
Deng, G., Zhao, DL., Li, GC. et al. Combination Therapy of Transcatheter Arterial Chemoembolization and Arterial Administration of Antiangiogenesis on VX2 Liver Tumor. Cardiovasc Intervent Radiol 34, 824–832 (2011). https://doi.org/10.1007/s00270-011-0179-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-011-0179-x